Pharmaceuticals

Preeclampsia Drugs Market 2026–2035 expanding with maternal healthcare focus

March 24, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Preeclampsia Drugs Market During The Forecast Period 2026–2030?

The preeclampsia drugs market size has seen rapid growth in recent years. It is projected to expand from $1.37 billion in 2025 to $1.52 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.6%. The factors influencing the growth during the historic period encompassed limited awareness of preeclampsia management, a reliance on traditional therapies, an absence of advanced monitoring technologies, inadequate hospital infrastructure, and low investment in maternal health drugs.

The preeclampsia drugs market is projected for significant expansion over the coming years. This market is anticipated to reach $2.37 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.8%. This projected growth stems from several factors, including innovations in drug formulations, an expanding healthcare infrastructure, an escalating need for outpatient maternal care, the incorporation of digital health solutions, and intensified research and development in precision medicine specifically for pregnancy complications. Key trends during this period are characterized by an increasing occurrence of preeclampsia in pregnant women, the emergence of new antihypertensive medications, a heightened emphasis on monitoring maternal and fetal health, the expansion of distribution channels via hospital pharmacies and specialty clinics, and the use of combination therapies for more severe instances.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13025&type=smp

Which Major Factors Are Driving The Expansion Of The Preeclampsia Drugs Market?

The increasing incidence of diabetes among expectant mothers is projected to stimulate the expansion of the preeclampsia drug market moving forward. Diabetes is a chronic metabolic condition marked by elevated blood glucose levels. Preeclampsia, a serious condition during pregnancy, is characterized by high blood pressure and organ damage. Metformin, a preeclampsia medication, is commonly prescribed for pregnant women with preterm preeclampsia. For example, in June 2024, data from the National Health Service, a UK government department, revealed that in 2023, the NHS identified over half a million (549,000) new individuals in England at risk of developing type 2 diabetes. This increased the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330, representing a significant rise compared to 3,065,825 in 2022, an increase of nearly 20%. Therefore, the growing number of diabetes cases among pregnant women will be a key driver for the preeclampsia drug market.

What Market Segments Are Evaluated Within The Preeclampsia Drugs Market?

The preeclampsia drugs market covered in this report is segmented –

1) By Type: Mild Preeclampsia, Severe Preeclampsia

2) By Treatment: Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication

3) By Route of Administration: Oral, Parenteral, Other Route of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users

Subsegments:

1) By Mild Preeclampsia: Blood Pressure Management

2) By Severe Preeclampsia: Antihypertensive Medications, Magnesium Sulfate Therapy

What Industry Trends Are Redefining The Preeclampsia Drugs Market?

Leading entities within the preeclampsia medicine market are concentrating their efforts on creating sophisticated treatments, including small interfering RNA (siRNA) therapies, aiming to tackle significant unmet medical requirements through innovative modes of operation. Investigational siRNA therapies represent a category of drugs formulated to deactivate or suppress particular genes implicated in disease causation, thereby providing a precise treatment methodology. As an illustration, during March 2023, the US-based biopharmaceutical company, Comanche Biopharma Corp., announced that the Food and Drug Administration (FDA) had granted approval for an investigational new drug (IND) application pertaining to CBP-4888, Comanche’s distinctive siRNA therapy for managing preeclampsia. CBP-4888 functions as a subcutaneously administered siRNA therapy that diminishes the production of soluble fms-like tyrosine kinase-1 (sFLT1) within the placenta. The primary factor contributing to preeclampsia is the placenta’s excessive generation of the protein sFLT1, which subsequently enters the maternal bloodstream. This treatment, CBP-4888, has the potential to mitigate preeclampsia symptoms like elevated blood pressure and organ impairment, potentially enabling a secure prolongation of pregnancy.

Who Are The Top Market Participants Influencing The Preeclampsia Drugs Market?

Major companies operating in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Boehringer Ingelheim Group, Viatris Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Mallinckrodt Pharmaceuticals Limited, Union Chimique Belge SA, Kyowa Kirin Co Ltd, Comanche Biopharma Corp

Read the full preeclampsia drugs market report here:

https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

Which Region Currently Holds The Largest Share Of The Preeclampsia Drugs Market?

North America was the largest region in the preeclampsia drugs market in 2025. The regions covered in the preeclampsia drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Preeclampsia Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13025&type=smp

Browse Through More Reports Similar to the Global Preeclampsia Drugs Market 2026, By The Business Research Company

Preeclampsia Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

Fertility Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/fertility-drugs-global-market-report

Epilepsy Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/epilepsy-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795